06:45 AM EDT, 10/28/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) reported Q3 non-GAAP net income Tuesday of $11.83 per diluted share, down from $12.46 a year earlier.

Analysts polled by FactSet expected $9.65.

Revenue for the quarter ended Sept. 30 was $3.75 billion, up from $3.72 billion a year earlier.

Analysts surveyed by FactSet expected $3.59 billion.

Shares of the company were up more than 5% in recent premarket activity.